InRange Study

All relevant safety information about adverse reactions, precautions, and relevant contraindications can be found on the product page HERE.

InRange - the first randomised, Phase 4 study to use Time-In-Range (TIR) as the primary endpoint to compare second generation basal insulin analogues Toujeo® Insulin Glargine 300U/ml and insulin degludec 100U/mL in people with T1DM.

InRange Clinical Summary

Download this clinical summary about the InRange study and learn more about the study design, the key findings and more.

Download

Time in Range Guide

View the guide below to find out more about the impact of time in range on your patients.

View guide

See more from science

Toujeo

Toujeo^® is indicated as treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years.

More about Toujeo

Patient Materials

Find resources and support for your patients who have been prescribed Toujeo^®. This section will help you to help your patients understand the basis of living and staying well with diabetes and how to have a a positive start and experience with Toujeo^®.

Access patient materials